ZFIN ID: ZDB-FISH-150901-9593
Fish name: tp53zdf1/zdf1; nn1002Tg
Genotype: tp53zdf1/zdf1; nn1002Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by tp53zdf1/zdf1; nn1002Tg
Human Disease Conditions Citations
hepatocellular carcinoma control (2)
GENE EXPRESSION
Gene expression in tp53zdf1/zdf1; nn1002Tg
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions Fig. 1 with image from Lu et al., 2013
mCherry standard conditions Fig. 1 with image from Lu et al., 2013
PHENOTYPE
Phenotype in tp53zdf1/zdf1; nn1002Tg
Phenotype Conditions Figures
female organism increased weight, abnormal increased food availability Fig. S1 from Yang et al., 2019
female organism increased weight, abnormal high fat Fig. S1 from Yang et al., 2019
hepatocyte fatty, abnormal standard conditions Fig. 2 with image from Lu et al., 2013
hepatocyte hyperplastic, abnormal standard conditions Fig. 2 with image,  Fig. 5 with image from Lu et al., 2013
hepatocyte mitotic cell cycle increased frequency, abnormal standard conditions Fig. 2 with image,  Fig. 5 with image from Lu et al., 2013
hepatocyte nucleolus prominent, abnormal standard conditions Fig. 2 with image,  Fig. 5 with image from Lu et al., 2013
hepatocyte nucleus increased size, abnormal standard conditions Fig. 2 with image,  Fig. 5 with image from Lu et al., 2013
liver cdk2 expression amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver cdk1 expression amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver cdk1 expression amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver ccne1 expression amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver ccne1 expression amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver cdk2 expression amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver aldh7a1 expression decreased amount, abnormal increased food availability Figure 7 with image from Yang et al., 2019
liver gck expression decreased amount, abnormal high fat Figure 7 with image from Yang et al., 2019
liver gck expression decreased amount, abnormal increased food availability Figure 7 with image from Yang et al., 2019
liver cdk1 expression decreased amount, abnormal high fat Figure 2 with image from Yang et al., 2019
liver acat2 expression decreased amount, abnormal increased food availability Figure 7 with image from Yang et al., 2019
liver acat2 expression decreased amount, abnormal high fat Figure 7 with image from Yang et al., 2019
liver ccne1 expression decreased amount, abnormal high fat Figure 2 with image from Yang et al., 2019
liver aldh7a1 expression decreased amount, abnormal control Figure 7 with image from Yang et al., 2019
liver scd expression decreased amount, abnormal increased food availability Figure 7 with image from Yang et al., 2019
liver gck expression decreased amount, abnormal control Figure 7 with image from Yang et al., 2019
liver pik3ca expression decreased amount, abnormal high fat Figure 7 with image from Yang et al., 2019
liver pik3ca expression decreased amount, abnormal increased food availability Figure 7 with image from Yang et al., 2019
liver dysplastic, abnormal control Fig. 5 with image from Lin et al., 2019
liver hyperplastic, abnormal high fat Figure 3 with image,  Figure 4 with image from Yang et al., 2019
liver hyperplastic, abnormal increased food availability Figure 3 with image,  Figure 4 with image from Yang et al., 2019
liver hyperplastic, abnormal control Fig. 5 with image from Lin et al., 2019
Figure 3 with image,  Figure 4 with image from Yang et al., 2019
liver fasn expression increased amount, abnormal high fat Figure 2 with image from Yang et al., 2019
liver pik3ca expression increased amount, abnormal control Figure 7 with image from Yang et al., 2019
liver cdk2 expression increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver cdk2 expression increased amount, abnormal high fat Figure 2 with image from Yang et al., 2019
liver srebf1 expression increased amount, abnormal increased food availability Figure 2 with image from Yang et al., 2019
liver scd expression increased amount, abnormal high fat Figure 7 with image from Yang et al., 2019
liver pparg expression increased amount, abnormal increased food availability Figure 2 with image from Yang et al., 2019
liver aldh7a1 expression increased amount, abnormal high fat Figure 7 with image from Yang et al., 2019
liver srebf1 expression increased amount, abnormal high fat Figure 2 with image from Yang et al., 2019
liver ccne1 expression increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver cdk1 expression increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver scd expression increased amount, abnormal control Figure 7 with image from Yang et al., 2019
liver inflamed, abnormal standard conditions Fig. 2 with image,  Fig. 5 with image from Lu et al., 2013
liver structure, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver structure, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver apoptotic process increased occurrence, abnormal standard conditions Fig. 3 with image from Lu et al., 2013
liver hepatic tumor increased occurrence, abnormal standard conditions Fig. 2 with image,  Fig. 5 with image from Lu et al., 2013
liver hepatocellular carcinoma amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver hepatocellular carcinoma amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver hepatocellular carcinoma increased amount, abnormal increased food availability Figure 4 with image from Yang et al., 2019
liver hepatocellular carcinoma increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver hepatocellular carcinoma increased amount, exacerbated high fat Figure 4 with image from Yang et al., 2019
liver hepatocyte morphology, abnormal high fat Figure 3 with image,  Figure 4 with image from Yang et al., 2019
liver hepatocyte morphology, abnormal control Figure 4 with image from Yang et al., 2019
liver lipid amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver lipid amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver lipid increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
Figure 3 with image from Yang et al., 2019
liver lipid increased amount, exacerbated high fat Figure 4 with image from Yang et al., 2019
male organism increased weight, abnormal high fat Fig. S1 from Yang et al., 2019
male organism increased weight, abnormal increased food availability Fig. S1 from Yang et al., 2019
whole organism increased weight, abnormal increased food availability Fig. S1 from Yang et al., 2019
whole organism increased weight, abnormal high fat Fig. S1 from Yang et al., 2019

CITATIONS  (5)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.